Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. (Nasdaq: PRME) is a biotechnology company that describes itself as committed to delivering a new class of differentiated one-time curative genetic therapies using its proprietary Prime Editing platform. The PRME news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how this Prime Editing strategy progresses from research to clinical data and corporate milestones.
According to its public announcements, Prime Medicine is advancing a diversified portfolio of investigational programs focused on liver, lung, and immunology and oncology. News items highlight specific programs such as PM577 for H1069Q-driven Wilson’s Disease, PM647 for Alpha-1 Antitrypsin Deficiency, an in vivo Cystic Fibrosis program supported by the Cystic Fibrosis Foundation, and PM359 for p47phox chronic granulomatous disease. Updates may include preclinical data presentations, first-in-human clinical data, and information about how Prime Editing is being applied across these indications.
Investors and observers can also use the PRME news page to follow corporate developments disclosed by the company, such as participation in healthcare and genetic medicines conferences, leadership appointments, financing transactions, and strategic collaborations, including efforts with Bristol Myers Squibb on Prime Edited CAR-T products. Because Prime Medicine regularly issues press releases in connection with quarterly financial results, pipeline updates, and investor events, the news stream offers a way to track changes in its pipeline priorities, regulatory plans, and capital markets activity over time.
By reviewing the PRME news feed, users can see how Prime Medicine communicates progress on its Prime Editing platform, key disease programs, and business strategy. Bookmarking this page provides a single location to review recent announcements, clinical and preclinical data disclosures, and other material updates that the company has chosen to release publicly.
Prime Medicine (Nasdaq: PRME) announced that Allan Reine, M.D., CEO, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco.
A live audio webcast will be available under Events & Presentations on the company's website at www.primemedicine.com, and a replay will remain accessible on the Prime Medicine website for 90 days after the event.
Prime Medicine (Nasdaq: PRME) announced publication in the New England Journal of Medicine of Phase 1/2 data for PM359, its investigational autologous HSC product for p47phox chronic granulomatous disease (CGD), with results also presented at the 67th ASH Annual Meeting (Dec 6-9, 2025).
Two patients showed rapid neutrophil and platelet engraftment, achieving 69% and 83% DHR+ neutrophils by Day 30 (above a 20% clinical threshold), durable NADPH oxidase activity, early clinical benefit (cessation of mesalamine in Patient 1; marked fecal calprotectin reduction and symptom improvement in Patient 2), and no clinically significant adverse events attributed to PM359; observed toxicities were consistent with busulfan-based conditioning.
Prime Medicine (Nasdaq: PRME) announced that Allan Reine, M.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 11:15 a.m. ET in Coral Gables, FL.
A live audio webcast will be available under “Events & Presentations” in the News & Events section of the company website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the event.
Prime Medicine (Nasdaq: PRME) announced that Allan Reine, M.D., Chief Executive Officer, will speak in a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 at 12:00 noon GMT (7:00 a.m. ET) in London.
A live audio webcast will be available under “Events & Presentations” in the News & Events section of the company website at www.primemedicine.com, and a replay will be accessible on the website for 90 days after the event.
Prime Medicine (NASDAQ: PRME) reported Q3 2025 results and provided program updates on Nov 7, 2025. Key items: WD IND/CTA expected in H1 2026 (corrected timeline) with initial clinical data expected in 2027; PM647 nominated for AATD with IND/CTA planned mid-2026 and first clinical readouts in 2027; new preclinical PM577 data to be presented at AASLD (Nov 9, 2025).
Financials: R&D $44.0M, G&A $11.2M, net loss $50.6M for Q3; cash, cash equivalents and investments totaled $227.0M as of Sep 30, 2025, and management expects cash into 2027 based on current plans. Leadership: appointed Matthew Hawryluk as Chief Business Officer. Virtual KOL event on Nov 12, 2025 at 8:00am ET to discuss WD strategy.
Prime Medicine (Nasdaq: PRME) reported Q3 2025 results and business updates on Nov 7, 2025. Key program milestones include nomination of PM647 for AATD with preclinical restoration of M-AAT into the healthy human range in humanized mice, and new preclinical PM577 data for Wilson’s Disease to be presented at AASLD on Nov 9, 2025.
The company expects to file an IND/CTA for AATD in mid-2026 and for Wilson’s Disease in the first half of 2027, with initial clinical data for both programs expected in 2027. Q3 cash and equivalents were $227.0M, and management says cash of $213.3M as of Sept 30, 2025 is sufficient to fund operations into 2027.
Prime Medicine (Nasdaq: PRME) appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer effective Nov 3, 2025. Dr. Hawryluk will lead corporate and business development, corporate strategy, and alliance management to expand Prime Editing through strategic partnerships.
He brings nearly two decades of BD and corporate leadership, including a prior role as CBO at AIRNA where he helped secure an oversubscribed $155 million Series B, and earlier transactions totaling $2.5 billion in potential value at Gritstone bio. The release also notes Prime’s earlier 2025 clinical data showing initial human safety and efficacy for Prime Editing.
Prime Medicine (Nasdaq: PRME) will host a virtual KOL event on Nov 12, 2025 at 8:00am ET to present its liver disease franchise and Wilson’s Disease strategy. The company said it remains on track to file an IND/CTA for PM577 in the first half of 2026, with initial clinical data expected in 2027. Presenters include company management and Dr. Michael Schilsky, covering Prime Editing platform modularity, the unmet need in Wilson’s Disease, and development plans. The live webcast and presentation materials will be available on Prime Medicine’s investor relations site, with an archived replay after the event.
Prime Medicine (Nasdaq: PRME) announced management will participate in two investor conferences in October 2025. A fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference will be available on demand beginning October 14, 2025, with virtual 1x1 meetings on October 15, 2025. Allan Reine, M.D., will join a panel, “Genome Editing: Next Wave Technologies,” and host 1x1 meetings at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025 at 8:45 a.m. ET in New York.
Live audio webcasts and replays will be available under Events & Presentations on the company website, with replays accessible for 90 days after each event.
Prime Medicine (Nasdaq: PRME), a biotechnology company focused on curative genetic therapies, has announced its participation in two upcoming investor conferences in September 2025:
The company will present at Citi's 2025 Biopharma Back to School Conference on September 2 at 4:45 p.m. ET in Boston, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 1:05 p.m. ET in New York. Live webcasts will be available on Prime Medicine's website, with replays accessible for 90 days after each event.
FAQ
What is the current stock price of Prime Medicine (PRME)?
What is the market cap of Prime Medicine (PRME)?
